Luye Pharma Group Ltd. is an investment holding company, which engages in the developing, producing, marketing, and selling of pharmaceutical products. The company is headquartered in Yantai, Shandong. The company went IPO on 2014-07-09. The firm operates four segments, including Oncology Drugs segment, Cardiovascular System Drugs segment, Alimentary Tract and Metabolism Drugs segment, and Central Nervous System Drugs segment. The Oncology Drugs segment provides Lipusu, Boyounuo, Baituowei, CMNa and Mimeixin and other drugs. The Cardiovascular System Drugs segment provides Xuezhikang, Oukai and Maitongna and other drugs. The Alimentary Tract and Metabolism Drugs segment provides Bei Xi and other drugs. The Central Nervous System Drugs segment provides Seroquel, Ruoxinlin, Rykindo, Meibirui and Jinyouping and other drugs.
Follow-Up Questions
What is the price performance of LYPHF stock?
The current price of LYPHF is $0, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Luye Pharma Group Ltd?
Luye Pharma Group Ltd belongs to Pharmaceuticals industry and the sector is Health Care
What is Luye Pharma Group Ltd market cap?
Luye Pharma Group Ltd's current market cap is $0
Is Luye Pharma Group Ltd a buy, sell, or hold?
According to wall street analysts, 4 analysts have made analyst ratings for Luye Pharma Group Ltd, including 3 strong buy, 3 buy, 2 hold, 0 sell, and 3 strong sell
